Barclays (LON:BARC) analyst Balaji Prasad maintained a Buy rating on Ligand Pharma (NASDAQ:LGND) on Thursday, setting a price target of $185, which is approximately 22.74% above the present share price of $150.72.
Prasad expects Ligand Pharma to post earnings per share (EPS) of $0.82 for the fourth quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Ligand Pharma, with an average price target of $247.5.
The analysts price targets range from a high of $310 to a low of $185.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $64.84 million and a net profit of $15.71 million. The company's market cap is $2.52 billion.
According to TipRanks.com, Barclays analyst Balaji Prasad is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 4.6% and a 46.48% success rate.
Ligand Pharmaceuticals , Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.